Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 84 | 2024 | 22030 | 4.550 |
Why?
|
Survivors | 40 | 2024 | 2371 | 3.590 |
Why?
|
Medical Oncology | 19 | 2022 | 2312 | 1.870 |
Why?
|
Primary Health Care | 17 | 2024 | 4653 | 1.470 |
Why?
|
Breast Neoplasms | 52 | 2022 | 21017 | 1.410 |
Why?
|
Physicians, Primary Care | 4 | 2023 | 624 | 1.240 |
Why?
|
Mammography | 12 | 2020 | 2427 | 1.210 |
Why?
|
Continuity of Patient Care | 7 | 2023 | 1067 | 1.200 |
Why?
|
Patient Education as Topic | 13 | 2020 | 2307 | 0.910 |
Why?
|
Head and Neck Neoplasms | 4 | 2022 | 2882 | 0.890 |
Why?
|
Neoplasm Recurrence, Local | 20 | 2022 | 9273 | 0.870 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 9 | 2017 | 936 | 0.860 |
Why?
|
Delivery of Health Care | 18 | 2024 | 5331 | 0.830 |
Why?
|
Patient Care Planning | 7 | 2019 | 907 | 0.790 |
Why?
|
Delivery of Health Care, Integrated | 4 | 2020 | 932 | 0.780 |
Why?
|
Patient Preference | 6 | 2022 | 921 | 0.750 |
Why?
|
Dental Care | 1 | 2024 | 279 | 0.740 |
Why?
|
Delayed Diagnosis | 4 | 2020 | 463 | 0.740 |
Why?
|
Patient Acceptance of Health Care | 9 | 2018 | 3175 | 0.710 |
Why?
|
Decision Making | 10 | 2020 | 3915 | 0.680 |
Why?
|
Patient-Centered Care | 5 | 2024 | 1415 | 0.680 |
Why?
|
Neoplasms, Second Primary | 6 | 2023 | 1056 | 0.660 |
Why?
|
Humans | 177 | 2024 | 758381 | 0.640 |
Why?
|
Long-Term Care | 4 | 2017 | 631 | 0.610 |
Why?
|
Quality of Life | 17 | 2024 | 13286 | 0.610 |
Why?
|
Health Services Accessibility | 5 | 2024 | 5403 | 0.600 |
Why?
|
Narration | 1 | 2019 | 219 | 0.570 |
Why?
|
Telemedicine | 5 | 2022 | 3018 | 0.570 |
Why?
|
Physical Endurance | 1 | 2019 | 362 | 0.560 |
Why?
|
Aftercare | 2 | 2019 | 910 | 0.540 |
Why?
|
Mastectomy, Segmental | 5 | 2017 | 972 | 0.530 |
Why?
|
Quality of Health Care | 6 | 2024 | 4317 | 0.530 |
Why?
|
Attitude of Health Personnel | 9 | 2019 | 3867 | 0.520 |
Why?
|
Deductibles and Coinsurance | 4 | 2019 | 316 | 0.520 |
Why?
|
Communication | 7 | 2018 | 3846 | 0.500 |
Why?
|
Workflow | 1 | 2020 | 850 | 0.500 |
Why?
|
Running | 1 | 2019 | 483 | 0.480 |
Why?
|
Attitude to Health | 3 | 2019 | 2025 | 0.470 |
Why?
|
Mass Screening | 8 | 2020 | 5425 | 0.470 |
Why?
|
Early Detection of Cancer | 10 | 2024 | 3211 | 0.470 |
Why?
|
General Practitioners | 1 | 2014 | 101 | 0.420 |
Why?
|
Practice Guidelines as Topic | 8 | 2024 | 7377 | 0.410 |
Why?
|
Breast Self-Examination | 2 | 2002 | 33 | 0.400 |
Why?
|
Patient Participation | 6 | 2020 | 1436 | 0.400 |
Why?
|
United States | 36 | 2024 | 72140 | 0.390 |
Why?
|
Referral and Consultation | 3 | 2020 | 3586 | 0.390 |
Why?
|
Insurance Coverage | 4 | 2018 | 1933 | 0.390 |
Why?
|
Patient Care Management | 2 | 2017 | 302 | 0.390 |
Why?
|
Medical Indigency | 1 | 2011 | 63 | 0.390 |
Why?
|
Internal Medicine | 3 | 2021 | 1048 | 0.370 |
Why?
|
Appointments and Schedules | 1 | 2014 | 441 | 0.360 |
Why?
|
Mastectomy | 7 | 2008 | 1832 | 0.360 |
Why?
|
Evidence-Based Medicine | 4 | 2019 | 3671 | 0.350 |
Why?
|
Population Surveillance | 2 | 2020 | 2606 | 0.350 |
Why?
|
Evidence-Based Practice | 1 | 2014 | 494 | 0.350 |
Why?
|
Ovarian Neoplasms | 2 | 2022 | 4876 | 0.340 |
Why?
|
Physicians | 4 | 2019 | 4581 | 0.340 |
Why?
|
Pandemics | 6 | 2022 | 8611 | 0.340 |
Why?
|
Employment | 1 | 2016 | 1112 | 0.340 |
Why?
|
Insurance, Health | 5 | 2019 | 2495 | 0.340 |
Why?
|
Palliative Care | 4 | 2024 | 3570 | 0.340 |
Why?
|
Medication Adherence | 2 | 2011 | 2155 | 0.340 |
Why?
|
Female | 94 | 2024 | 390316 | 0.330 |
Why?
|
Terminal Care | 1 | 2021 | 1750 | 0.330 |
Why?
|
Clinical Competence | 3 | 2023 | 4775 | 0.330 |
Why?
|
Physician-Patient Relations | 7 | 2016 | 3242 | 0.320 |
Why?
|
Survival Rate | 8 | 2017 | 12721 | 0.310 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3076 | 0.310 |
Why?
|
Carcinoma, Ductal, Breast | 3 | 2014 | 1096 | 0.310 |
Why?
|
Colonic Neoplasms | 1 | 2020 | 2523 | 0.310 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3196 | 0.310 |
Why?
|
Vulvar Neoplasms | 2 | 2024 | 263 | 0.300 |
Why?
|
Patient Compliance | 4 | 2014 | 2685 | 0.300 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2014 | 3990 | 0.300 |
Why?
|
Patient Care Team | 3 | 2017 | 2504 | 0.290 |
Why?
|
Uterine Neoplasms | 3 | 2023 | 1439 | 0.290 |
Why?
|
Tamoxifen | 2 | 2011 | 963 | 0.290 |
Why?
|
Aromatase Inhibitors | 1 | 2011 | 511 | 0.290 |
Why?
|
Patient Satisfaction | 6 | 2021 | 3446 | 0.280 |
Why?
|
Women's Health | 4 | 2009 | 2057 | 0.280 |
Why?
|
Physicians, Family | 1 | 2009 | 349 | 0.280 |
Why?
|
Middle Aged | 62 | 2024 | 219560 | 0.280 |
Why?
|
Carcinoma in Situ | 2 | 2009 | 796 | 0.270 |
Why?
|
Fear | 3 | 2020 | 1462 | 0.270 |
Why?
|
Breast | 4 | 2019 | 1963 | 0.270 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2014 | 951 | 0.270 |
Why?
|
Adaptation, Psychological | 6 | 2022 | 2629 | 0.260 |
Why?
|
Aged | 50 | 2024 | 168217 | 0.260 |
Why?
|
Adult | 52 | 2024 | 219916 | 0.260 |
Why?
|
Research | 5 | 2023 | 1976 | 0.260 |
Why?
|
Interdisciplinary Communication | 2 | 2014 | 931 | 0.250 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2018 | 1530 | 0.250 |
Why?
|
Lymphoma | 1 | 2014 | 1896 | 0.240 |
Why?
|
Health Promotion | 1 | 2017 | 2202 | 0.240 |
Why?
|
Nomograms | 3 | 2015 | 237 | 0.240 |
Why?
|
Uterine Cervical Neoplasms | 3 | 2023 | 2016 | 0.240 |
Why?
|
Internet | 3 | 2014 | 3082 | 0.230 |
Why?
|
Patient Care | 1 | 2009 | 622 | 0.230 |
Why?
|
Endometrial Neoplasms | 3 | 2023 | 1357 | 0.220 |
Why?
|
Women | 1 | 2005 | 225 | 0.220 |
Why?
|
Estrogen Replacement Therapy | 2 | 2009 | 1206 | 0.220 |
Why?
|
Medical Records Systems, Computerized | 1 | 2009 | 1190 | 0.220 |
Why?
|
Health Services Research | 4 | 2021 | 1812 | 0.220 |
Why?
|
Prostatic Neoplasms | 4 | 2020 | 11336 | 0.210 |
Why?
|
Drug Costs | 1 | 2011 | 1179 | 0.210 |
Why?
|
Health Expenditures | 4 | 2018 | 2348 | 0.200 |
Why?
|
Carcinosarcoma | 1 | 2023 | 104 | 0.200 |
Why?
|
Physical Examination | 1 | 2008 | 1244 | 0.200 |
Why?
|
Carcinoma, Endometrioid | 2 | 2023 | 276 | 0.200 |
Why?
|
Documentation | 1 | 2008 | 892 | 0.200 |
Why?
|
Magnetic Resonance Imaging | 6 | 2020 | 36285 | 0.190 |
Why?
|
Cross-Sectional Studies | 13 | 2024 | 25953 | 0.190 |
Why?
|
Policy | 2 | 2023 | 509 | 0.190 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2023 | 217 | 0.190 |
Why?
|
Health Maintenance Organizations | 3 | 2009 | 660 | 0.170 |
Why?
|
Latin America | 1 | 2021 | 405 | 0.170 |
Why?
|
Erythema Nodosum | 1 | 2000 | 31 | 0.170 |
Why?
|
Antibodies, Antiphospholipid | 1 | 2000 | 71 | 0.170 |
Why?
|
Antineoplastic Agents | 6 | 2023 | 13591 | 0.170 |
Why?
|
Aged, 80 and over | 22 | 2020 | 58681 | 0.170 |
Why?
|
Neoplasm Staging | 11 | 2019 | 11152 | 0.170 |
Why?
|
Young Adult | 11 | 2022 | 58808 | 0.160 |
Why?
|
Managed Care Programs | 3 | 2014 | 939 | 0.160 |
Why?
|
Oral Health | 1 | 2024 | 486 | 0.160 |
Why?
|
Education, Continuing | 1 | 2019 | 114 | 0.160 |
Why?
|
Needs Assessment | 3 | 2018 | 1141 | 0.160 |
Why?
|
Reproduction | 1 | 2023 | 646 | 0.150 |
Why?
|
Sensitivity and Specificity | 7 | 2024 | 14641 | 0.150 |
Why?
|
Psychotherapy, Group | 1 | 2002 | 412 | 0.150 |
Why?
|
Mental Processes | 1 | 2019 | 245 | 0.150 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2023 | 708 | 0.150 |
Why?
|
Life Style | 2 | 2020 | 3886 | 0.150 |
Why?
|
Male | 32 | 2024 | 358742 | 0.150 |
Why?
|
Hypothyroidism | 1 | 2022 | 665 | 0.140 |
Why?
|
Depression | 5 | 2023 | 8057 | 0.140 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2018 | 255 | 0.130 |
Why?
|
Oral Hygiene | 1 | 2017 | 129 | 0.130 |
Why?
|
Critical Pathways | 1 | 2020 | 473 | 0.130 |
Why?
|
Health Services Needs and Demand | 3 | 2019 | 1401 | 0.130 |
Why?
|
Hot Flashes | 2 | 2009 | 328 | 0.130 |
Why?
|
Attitude | 2 | 2014 | 776 | 0.130 |
Why?
|
Longitudinal Studies | 5 | 2019 | 14481 | 0.130 |
Why?
|
Papillomavirus Infections | 2 | 2019 | 1612 | 0.130 |
Why?
|
Models, Theoretical | 2 | 2010 | 3561 | 0.130 |
Why?
|
Europe | 1 | 2022 | 3420 | 0.130 |
Why?
|
Delphi Technique | 3 | 2024 | 829 | 0.120 |
Why?
|
Curriculum | 2 | 2021 | 3717 | 0.120 |
Why?
|
Health Surveys | 5 | 2019 | 4060 | 0.120 |
Why?
|
Health Care Surveys | 4 | 2016 | 2432 | 0.120 |
Why?
|
Forecasting | 2 | 2017 | 2920 | 0.120 |
Why?
|
Information Dissemination | 1 | 2023 | 1128 | 0.120 |
Why?
|
China | 1 | 2020 | 2337 | 0.120 |
Why?
|
Professional Role | 1 | 2017 | 309 | 0.120 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2018 | 3527 | 0.110 |
Why?
|
Consumer Health Information | 1 | 2016 | 210 | 0.110 |
Why?
|
Consensus | 3 | 2022 | 3099 | 0.110 |
Why?
|
Anxiety | 4 | 2023 | 4538 | 0.110 |
Why?
|
Quality Assurance, Health Care | 2 | 2014 | 2167 | 0.110 |
Why?
|
SEER Program | 3 | 2014 | 1530 | 0.110 |
Why?
|
Vulnerable Populations | 1 | 2019 | 699 | 0.110 |
Why?
|
Educational Status | 1 | 2021 | 2513 | 0.110 |
Why?
|
Medicare | 1 | 2011 | 6741 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2019 | 1475 | 0.110 |
Why?
|
Healthcare Disparities | 2 | 2020 | 3362 | 0.100 |
Why?
|
Health Personnel | 4 | 2019 | 3311 | 0.100 |
Why?
|
Osteoporosis | 1 | 2022 | 1599 | 0.100 |
Why?
|
Interpersonal Relations | 1 | 2020 | 1433 | 0.100 |
Why?
|
Cohort Studies | 10 | 2019 | 41252 | 0.100 |
Why?
|
Boston | 3 | 2011 | 9304 | 0.100 |
Why?
|
Follow-Up Studies | 9 | 2021 | 39060 | 0.100 |
Why?
|
Adolescent | 12 | 2024 | 87888 | 0.100 |
Why?
|
Hematologic Neoplasms | 2 | 2021 | 1890 | 0.100 |
Why?
|
Caregivers | 3 | 2022 | 2224 | 0.100 |
Why?
|
Developing Countries | 1 | 2024 | 2866 | 0.100 |
Why?
|
Data Collection | 2 | 2012 | 3322 | 0.090 |
Why?
|
Exercise | 4 | 2022 | 5788 | 0.090 |
Why?
|
American Cancer Society | 2 | 2022 | 66 | 0.090 |
Why?
|
Self Report | 2 | 2020 | 3712 | 0.090 |
Why?
|
Anthracyclines | 1 | 2012 | 282 | 0.090 |
Why?
|
Sarcoma | 1 | 2021 | 1785 | 0.090 |
Why?
|
Decision Support Techniques | 1 | 2020 | 1996 | 0.090 |
Why?
|
Postmenopause | 2 | 2009 | 2509 | 0.090 |
Why?
|
Risk Assessment | 8 | 2024 | 23883 | 0.080 |
Why?
|
Carcinoma, Ductal | 1 | 2010 | 97 | 0.080 |
Why?
|
Pilot Projects | 4 | 2024 | 8554 | 0.080 |
Why?
|
Insurance Claim Review | 1 | 2014 | 737 | 0.080 |
Why?
|
Comorbidity | 3 | 2020 | 10495 | 0.080 |
Why?
|
Socioeconomic Factors | 5 | 2018 | 7817 | 0.080 |
Why?
|
Group Practice, Prepaid | 1 | 2008 | 15 | 0.080 |
Why?
|
Neoplasm Invasiveness | 5 | 2017 | 3617 | 0.080 |
Why?
|
Current Procedural Terminology | 1 | 2009 | 90 | 0.080 |
Why?
|
Health Behavior | 2 | 2018 | 2615 | 0.080 |
Why?
|
Pregnancy Complications | 3 | 2000 | 2942 | 0.080 |
Why?
|
Drug Substitution | 1 | 2011 | 288 | 0.080 |
Why?
|
Washington | 1 | 2009 | 312 | 0.080 |
Why?
|
Interprofessional Relations | 2 | 2014 | 989 | 0.070 |
Why?
|
Skin Neoplasms | 2 | 2024 | 5797 | 0.070 |
Why?
|
Melanoma | 2 | 2024 | 5691 | 0.070 |
Why?
|
Risk Factors | 13 | 2018 | 73806 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3227 | 0.070 |
Why?
|
Disease Progression | 2 | 2022 | 13468 | 0.070 |
Why?
|
Genetic Counseling | 1 | 2011 | 624 | 0.070 |
Why?
|
Prognosis | 8 | 2016 | 29558 | 0.070 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2017 | 1196 | 0.070 |
Why?
|
Research Design | 1 | 2023 | 6154 | 0.070 |
Why?
|
Neoplasm Metastasis | 3 | 2024 | 4901 | 0.070 |
Why?
|
Genital Neoplasms, Female | 2 | 2024 | 533 | 0.070 |
Why?
|
Time Factors | 4 | 2018 | 39873 | 0.070 |
Why?
|
Community Health Services | 1 | 2011 | 655 | 0.060 |
Why?
|
Intention | 1 | 2008 | 345 | 0.060 |
Why?
|
Psychometrics | 1 | 2015 | 3050 | 0.060 |
Why?
|
Gynecology | 2 | 2010 | 528 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2017 | 1791 | 0.060 |
Why?
|
Inservice Training | 1 | 2008 | 375 | 0.060 |
Why?
|
Professional Practice | 1 | 2007 | 313 | 0.060 |
Why?
|
Phenotype | 1 | 2023 | 16534 | 0.060 |
Why?
|
Smoking Cessation | 1 | 2017 | 2049 | 0.060 |
Why?
|
Treatment Outcome | 6 | 2023 | 64379 | 0.060 |
Why?
|
Registries | 4 | 2019 | 8176 | 0.060 |
Why?
|
Colorectal Neoplasms | 2 | 2014 | 6852 | 0.060 |
Why?
|
Child | 7 | 2024 | 79813 | 0.060 |
Why?
|
Health Care Costs | 1 | 2018 | 3245 | 0.060 |
Why?
|
Hormone Replacement Therapy | 1 | 2010 | 754 | 0.060 |
Why?
|
Obstetrics | 2 | 2010 | 667 | 0.060 |
Why?
|
Biopsy | 4 | 2019 | 6768 | 0.060 |
Why?
|
International Classification of Diseases | 1 | 2009 | 892 | 0.060 |
Why?
|
Medical History Taking | 1 | 2008 | 772 | 0.060 |
Why?
|
Ethics Committees, Research | 1 | 2005 | 196 | 0.060 |
Why?
|
Confidence Intervals | 1 | 2009 | 2925 | 0.060 |
Why?
|
Paget Disease, Extramammary | 1 | 2024 | 51 | 0.060 |
Why?
|
Biomedical Research | 1 | 2019 | 3417 | 0.050 |
Why?
|
Incidence | 4 | 2018 | 21273 | 0.050 |
Why?
|
Life Expectancy | 1 | 2010 | 1244 | 0.050 |
Why?
|
Physician's Role | 1 | 2009 | 917 | 0.050 |
Why?
|
Qualitative Research | 2 | 2013 | 2976 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 11709 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2024 | 8981 | 0.050 |
Why?
|
Professional-Patient Relations | 1 | 2008 | 727 | 0.050 |
Why?
|
Reproducibility of Results | 4 | 2019 | 20052 | 0.050 |
Why?
|
International Educational Exchange | 1 | 2002 | 49 | 0.050 |
Why?
|
Computers, Handheld | 1 | 2024 | 210 | 0.050 |
Why?
|
Cardiomyopathies | 1 | 2014 | 1944 | 0.050 |
Why?
|
Receptor, erbB-2 | 1 | 2012 | 2553 | 0.050 |
Why?
|
California | 2 | 2020 | 1419 | 0.050 |
Why?
|
Retrospective Studies | 13 | 2020 | 80170 | 0.050 |
Why?
|
Health Status | 3 | 2010 | 4069 | 0.050 |
Why?
|
Analgesics, Opioid | 1 | 2017 | 3765 | 0.050 |
Why?
|
Developed Countries | 1 | 2024 | 440 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2017 | 4023 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5246 | 0.050 |
Why?
|
Program Evaluation | 2 | 2019 | 2490 | 0.050 |
Why?
|
Health Status Indicators | 1 | 2006 | 970 | 0.050 |
Why?
|
Menopause | 1 | 2009 | 1639 | 0.050 |
Why?
|
Precancerous Conditions | 1 | 2007 | 977 | 0.040 |
Why?
|
beta 2-Glycoprotein I | 1 | 2000 | 28 | 0.040 |
Why?
|
Mass Media | 1 | 2003 | 301 | 0.040 |
Why?
|
Stroke | 1 | 2022 | 9696 | 0.040 |
Why?
|
Patient Selection | 1 | 2012 | 4244 | 0.040 |
Why?
|
Cranial Irradiation | 1 | 2022 | 390 | 0.040 |
Why?
|
Internship and Residency | 1 | 2000 | 5865 | 0.040 |
Why?
|
Massachusetts | 2 | 2010 | 8823 | 0.040 |
Why?
|
Connecticut | 1 | 2000 | 365 | 0.040 |
Why?
|
Guideline Adherence | 1 | 2010 | 2215 | 0.040 |
Why?
|
Medical Records | 1 | 2005 | 1406 | 0.040 |
Why?
|
New England | 1 | 2002 | 1053 | 0.040 |
Why?
|
Heart Failure | 2 | 2014 | 11594 | 0.040 |
Why?
|
Disease Management | 1 | 2010 | 2500 | 0.040 |
Why?
|
Thyrotropin | 1 | 2022 | 832 | 0.040 |
Why?
|
Problem-Based Learning | 1 | 2002 | 352 | 0.040 |
Why?
|
Case-Control Studies | 6 | 2015 | 22031 | 0.040 |
Why?
|
Age Factors | 4 | 2020 | 18357 | 0.040 |
Why?
|
Mammaplasty | 1 | 2007 | 1239 | 0.040 |
Why?
|
Family Practice | 2 | 2010 | 509 | 0.040 |
Why?
|
Osteitis | 1 | 1996 | 33 | 0.040 |
Why?
|
Logistic Models | 3 | 2018 | 13276 | 0.040 |
Why?
|
Hyperostosis | 1 | 1996 | 29 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2019 | 10146 | 0.030 |
Why?
|
Survival Analysis | 2 | 2016 | 10112 | 0.030 |
Why?
|
Algorithms | 2 | 2014 | 13959 | 0.030 |
Why?
|
Quadruplets | 1 | 1996 | 9 | 0.030 |
Why?
|
Immunoglobulin A | 1 | 2000 | 979 | 0.030 |
Why?
|
Minority Groups | 1 | 2023 | 1206 | 0.030 |
Why?
|
Genetic Testing | 2 | 2012 | 3530 | 0.030 |
Why?
|
Recurrence | 2 | 2016 | 8426 | 0.030 |
Why?
|
Odds Ratio | 3 | 2014 | 9650 | 0.030 |
Why?
|
ROC Curve | 2 | 2014 | 3563 | 0.030 |
Why?
|
Synovitis | 1 | 1996 | 215 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2019 | 13245 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2016 | 296 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2021 | 1098 | 0.030 |
Why?
|
Pregnancy | 5 | 2019 | 29742 | 0.030 |
Why?
|
Self Efficacy | 1 | 2019 | 631 | 0.030 |
Why?
|
Cervix Uteri | 1 | 2019 | 583 | 0.030 |
Why?
|
Fatigue | 1 | 2022 | 1542 | 0.030 |
Why?
|
Societies, Medical | 2 | 2019 | 3891 | 0.030 |
Why?
|
Multicenter Studies as Topic | 2 | 2012 | 1705 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2017 | 8530 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2020 | 1386 | 0.030 |
Why?
|
MEDLINE | 1 | 2013 | 119 | 0.030 |
Why?
|
Hysterectomy | 1 | 2019 | 904 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 546 | 0.030 |
Why?
|
Emotions | 1 | 2005 | 2734 | 0.030 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 1995 | 412 | 0.030 |
Why?
|
Clinical Coding | 1 | 2014 | 180 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2019 | 1121 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2018 | 1673 | 0.030 |
Why?
|
Biomedical Technology | 1 | 2014 | 209 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2019 | 5199 | 0.030 |
Why?
|
Glycoproteins | 1 | 2000 | 2205 | 0.020 |
Why?
|
Cancer Care Facilities | 1 | 2015 | 424 | 0.020 |
Why?
|
Anxiety Disorders | 1 | 2023 | 2714 | 0.020 |
Why?
|
Health Plan Implementation | 1 | 2014 | 336 | 0.020 |
Why?
|
Acne Vulgaris | 1 | 1996 | 356 | 0.020 |
Why?
|
Incidental Findings | 1 | 2016 | 694 | 0.020 |
Why?
|
Brachytherapy | 1 | 2019 | 1236 | 0.020 |
Why?
|
Autoantibodies | 1 | 2000 | 2118 | 0.020 |
Why?
|
Aspirin | 1 | 2022 | 3132 | 0.020 |
Why?
|
Genes, BRCA2 | 1 | 2014 | 603 | 0.020 |
Why?
|
Education, Medical | 1 | 2002 | 1725 | 0.020 |
Why?
|
Income | 1 | 2019 | 1872 | 0.020 |
Why?
|
Prevalence | 2 | 2019 | 15646 | 0.020 |
Why?
|
Genes, BRCA1 | 1 | 2014 | 765 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2011 | 17768 | 0.020 |
Why?
|
Diet | 2 | 2022 | 8003 | 0.020 |
Why?
|
Professional-Family Relations | 1 | 2013 | 495 | 0.020 |
Why?
|
Dyspareunia | 1 | 2009 | 48 | 0.020 |
Why?
|
Medical Audit | 1 | 2010 | 452 | 0.020 |
Why?
|
Mammary Glands, Human | 1 | 2010 | 203 | 0.020 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2012 | 675 | 0.020 |
Why?
|
Psoriasis | 1 | 1996 | 938 | 0.020 |
Why?
|
Health Resources | 1 | 2014 | 931 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2016 | 1780 | 0.020 |
Why?
|
Sweating | 1 | 2009 | 154 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2000 | 4540 | 0.020 |
Why?
|
Patient Transfer | 1 | 2014 | 777 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2014 | 2896 | 0.020 |
Why?
|
Tumor Burden | 1 | 2013 | 1893 | 0.020 |
Why?
|
Poverty | 1 | 2019 | 2692 | 0.020 |
Why?
|
Pain | 1 | 2022 | 5065 | 0.020 |
Why?
|
Awareness | 1 | 2011 | 644 | 0.020 |
Why?
|
Age Distribution | 1 | 2012 | 2882 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2012 | 2504 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2024 | 6313 | 0.020 |
Why?
|
Complementary Therapies | 1 | 2010 | 486 | 0.020 |
Why?
|
Skin | 1 | 2000 | 4464 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9599 | 0.020 |
Why?
|
Postal Service | 1 | 2005 | 95 | 0.020 |
Why?
|
Thyroid Neoplasms | 1 | 2018 | 2332 | 0.020 |
Why?
|
Peer Group | 1 | 2010 | 677 | 0.020 |
Why?
|
Mortality | 1 | 2016 | 2885 | 0.020 |
Why?
|
Probability | 1 | 2010 | 2467 | 0.010 |
Why?
|
Health Status Disparities | 1 | 2016 | 1832 | 0.010 |
Why?
|
Sexuality | 1 | 2006 | 179 | 0.010 |
Why?
|
Mental Health | 1 | 2018 | 3232 | 0.010 |
Why?
|
Breast Diseases | 1 | 2006 | 443 | 0.010 |
Why?
|
Quality Improvement | 1 | 2018 | 3806 | 0.010 |
Why?
|
Psychology | 1 | 2005 | 356 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 7985 | 0.010 |
Why?
|
Treatment Failure | 1 | 2009 | 2640 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2005 | 15638 | 0.010 |
Why?
|
Family | 1 | 2013 | 3188 | 0.010 |
Why?
|
Random Allocation | 1 | 2006 | 2385 | 0.010 |
Why?
|
Epidemiologic Research Design | 1 | 2005 | 368 | 0.010 |
Why?
|
Russia | 1 | 2002 | 381 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15225 | 0.010 |
Why?
|
Body Image | 1 | 2006 | 637 | 0.010 |
Why?
|
Breast Implants | 1 | 2005 | 409 | 0.010 |
Why?
|
Stroke Volume | 1 | 2014 | 5460 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2007 | 2675 | 0.010 |
Why?
|
Clinical Protocols | 1 | 2005 | 1436 | 0.010 |
Why?
|
Cause of Death | 1 | 2010 | 3674 | 0.010 |
Why?
|
Quality Indicators, Health Care | 1 | 2009 | 1797 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12096 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2012 | 11070 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2012 | 12440 | 0.010 |
Why?
|
Computer Simulation | 1 | 2010 | 6201 | 0.010 |
Why?
|
Aging | 1 | 1995 | 8651 | 0.010 |
Why?
|
Databases, Factual | 1 | 2012 | 7980 | 0.010 |
Why?
|
Indomethacin | 1 | 1996 | 326 | 0.010 |
Why?
|
Program Development | 1 | 2002 | 1297 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2012 | 4761 | 0.010 |
Why?
|
Chronic Disease | 1 | 2009 | 9266 | 0.010 |
Why?
|
France | 1 | 1996 | 499 | 0.010 |
Why?
|
Syndrome | 1 | 1996 | 3262 | 0.010 |
Why?
|
Birth Weight | 1 | 1996 | 2097 | 0.000 |
Why?
|
Pregnancy Outcome | 1 | 1996 | 2907 | 0.000 |
Why?
|